Senior Accountant, General Ledger, Europe

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

Not verified

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$106,409 U.S. median for this role

Projected growth (BLS Employment Projections)

+7.7% - Faster than average

Matched to SOC 13-2011 - Finance aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Finance From the posting source checked Jun 20, 2026

Seniority

Senior From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Accountant, General Ledger, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated individual with a background in the life sciences industry to play a critical role in the accounting team. Reporting directly to the Senior Director, Accounting Europe, this newly created role will support the daily accounting operations operations across multiple European entities. This role will be responsible for maintaining accurate financial records, supporting month-end and year-end US GAAP and local GAAP close activities, preparing journal entries and reconciliations, VAT reporting, and ensuring compliance with company policies, internal controls, and applicable accounting standards. The role is located in Basel, Switzerland. - Perform day-to-day general ledger accounting activities for European entities. - Prepare journal entries such as cash, prepayments, accruals, fixed assets, leases and other month-end close adjustments. - Support monthly, quarterly, and annual close processes in accordance with company timelines. - Prepare balance sheet reconciliations and investigate variances in a timely

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.